Thank you for the submission of your research manuscript to our journal. We have now received the enclosed reports on it.
Thank you for the submission of your research manuscript to our journal. We have now received the enclosed reports on it.
As you will see, the referees acknowledge that the findings are potentially interesting and novel. However, they also point out that no direct evidence is provided to support the conclusion that SLFN11 removes RPA from ssDNA, and that the effect of SLFN11 on HR may be indirect. The referees have several suggestions for how the study could be strengthened, and I think that all of them should be addressed, with the exception of generating point mutants of SLFN11 that do not interact with RPA. Upon cross-commenting referee 2 notes that generating point mutants would be outside the scope of this study, and referee 1 agrees.
Given these constructive comments, we would like to invite you to revise your manuscript with the understanding that the referee concerns must be fully addressed and their suggestions taken on board. Please address all referee concerns in a complete point-by-point response. Acceptance of the manuscript will depend on a positive outcome of a second round of review. It is EMBO reports policy to allow a single round of revision only and acceptance or rejection of the manuscript will therefore depend on the completeness of your responses included in the next, final version of the manuscript.
Revised manuscripts should be submitted within three months of a request for revision; they will otherwise be treated as new submissions. Please contact us if a 3-months time frame is not sufficient for the revisions so that we can discuss the issue further. You can either publish the study as a short report or as a full article. For short reports, the revised manuscript should not exceed 35,000 characters (including spaces and references) and 5 main plus 5 expanded view figures. The results and discussion section must further be combined, which will help to shorten the manuscript text by eliminating some redundancy that is inevitable when discussing the same experiments twice. Commonly used materials and methods can be moved to the supplementary information, however, please note that materials and methods essential for the understanding of the experiments described in the main text must remain in the main manuscript file. For a normal article there are no length limitations, but the results and discussion section must be separate and the entire materials and methods included in the main manuscript file.
Regarding data quantification, can you please specify the number "n" for how many experiments were performed, the bars and error bars (e.g. SEM, SD) and the test used to calculate p-values in the respective figure legends? This information is currently incomplete and must be provided in the figure legends. Please also include scale bars in all microscopy images.
We now strongly encourage the publication of original source data with the aim of making primary data more accessible and transparent to the reader. The source data will be published in a separate source data file online along with the accepted manuscript and will be linked to the relevant figure.
If you would like to use this opportunity, please submit the source data (for example scans of entire gels or blots, data points of graphs in an excel sheet, additional images, etc.) of your key experiments together with the revised manuscript. Please include size markers for scans of entire gels, label the scans with figure and panel number, and send one PDF file per figure or per figure panel.
When submitting your revised manuscript, we will require: -a complete author checklist, which you can download from our author guidelines (http://embor.embopress.org/authorguide#revision). Please insert page numbers in the checklist to indicate where the requested information can be found.
-a letter detailing your responses to the referee comments in Word format (.doc) -a Microsoft Word file (.doc) of the revised manuscript text -editable TIFF or EPS-formatted figure files in high resolution -a separate PDF file of any Supplementary information (in its final format)
We would also welcome the submission of cover suggestions, or motifs to be used by our Graphics Illustrator in designing a cover.
As part of the EMBO publication's Transparent Editorial Process, EMBO reports publishes online a Review Process File to accompany accepted manuscripts. This File will be published in conjunction with your paper and will include the referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript.
You are able to opt out of this by letting the editorial office know (emboreports@embo.org). If you do opt out, the Review Process File link will point to the following statement: "No Review Process File is available with this article, as the authors have chosen not to make the review process public in this case." I look forward to seeing a revised version of your manuscript when it is ready. Please let me know if you have questions or comments regarding the revision.
REFEREE REPORTS

Referee #1:
SLFN11 was shown by Pommier and others to impart cellular sensitivity to topoisomerase poisons and other DNA damaging agents when present in elevated amounts (Zoppoli, PNAS, 2012; Barretina, Nature 2012) . SLFN11 also has other functions (these are cited in the manuscript) and, based on its primary sequence, is presumed to have a RNA helicase activity. Understanding the biology of SLFN11 is clearly important and has direct relevance to cancer etiology.
In this study, Mu et al have conducted a proteomic analysis of SLFN11 and found the ssDNA binding protein RPA as an interactor. SLFN11 binds RPA1 and localizes to DNA damage in a manner that is dependent on its interaction with RPA. SLFN11 knockdown, knockout, and overexpression studies have shown that SLFN11 affects checkpoint maintenance, attenuates the dwell time of RPA on ssDNA associated with DNA damage, and also suppresses the level of homologous recombination. These effects of SLFN11 can explain the earlier observations by others regarding DNA damage sensitization of cells to DNA damage. The data are for the most part convincing and of a high quality, and the manuscript is reasonably well written. While I am enthusiastic about the study, there are a few issues that should be addressed before the paper is published.
Major Issues (in no particular order):
1. The SLFN11-RPA1 interface needs to be defined more. Does SLFN11 associate exclusively with the N-terminal interaction module of RPA1? Assuming that this is the case, and given that numerous RPA1-N interactors have been documented, it will be straightforward to do an alignment of the Cterminal region (missing in the delta 5 mutant) of SLFN11 with the mapped RPA1-N binding domains of the other known interactors to identify conserved residues to mutate. This will allow the authors to work with a point mutant rather than a truncation mutant that lacks 161 amino acid residues (as in the delta5 mutant). 2. At the minimum, the author should verify that the SLFN11 delta5 mutant does not localize to DNA damage. Ideally, this experiment should be done with a point mutant of SLNF11 that no longer interacts with RPA (see Point #1). 3. The authors should check their GST tagged K605M/D668A mutant protein (alongside the wild type protein) to make sure that it no longer hydrolyzes ATP. This will provide support to the conclusion that the (presumptive) helicase activity of SLFN11 is dispensable for the biological effects relevant for DNA damage checkpoint maintenance and repair. 4. The authors have the tool to estimate by immunoblotting the total number of molecules of SLFN11 in various cell lines relative to RPA copy number; this will inform us whether SLNF11 acts catalytically or stoichiometrically on RPA-ssDNA. 5. The authors should check the level of cellular RPA in these cell lines before and after DNA damage to be sure that the steady level of RPA is not affected by SLFN11. 6. Can the authors assure us that the co-IP and pulldown of SLFN11 with RPA or RPA1 was not caused by RNA/DNA? This is a real concern knowing that these proteins bind nucleic acid. 7. I question the model regarding SLFN11 function (Fig. 7D) as it ignores the fact that RPA removal should facilitate the loading of the recombinase protein RAD51. It is somewhat counter-intuitive that RPA removal should lead to a homologous recombination deficiency. At the minimum, the authors should check the RAD51 level in cells expressing varying amounts of SLFN11 and mutants before and after DNA damage and look at RAD51 foci formation. They have all the tools to accomplish this. 8. I have a major issue with the claim that SLFN11 "removes" RPA from ssDNA. The data show that there is less RPA at DNA damage sites if SLFN11 is overexpressed, but there is no direct evidence to support the claim of RPA removal. For instance, the results could be explained if SNLF11 recruits a ssDNA endonuclease (in fact, SLFN11 itself could be a nuclease) to clip RPAcoated DNA to release RPA-ssDNA particles rather than removing RPA from ssDNA. To avoid misleading the field, the authors must temper their conclusion regarding RPA removal. It would be fine to speculate in the Discussion that SLFN11 may somehow remove RPA from ssDNA along with the above and other possibilities. Discuss also the possibility that the SLFN11-associated nuclease may be activated by RPA bound to ssDNA. 9. The Pommier PNAS paper did a nice job documenting the effect of SLFN11 in sensitizing cells to topoisomerase poisons. The authors should discuss the PNAS study more thoroughly.
Minor Issues: 10. Fig. 2E : the lanes in the two panels are misaligned. Please fix this problem. 11. I can't figure out why the authors cite so many RPA references (page 4 onto page 5). Wouldn't a review or two suffice? 12. Page 8, first paragraph: suggest deleting "Strikingly", as, though important, there is nothing striking about finding another RPA binding protein. Just say "Reproducibly,....". 13. Page 14: "depletion of SLFN11.... unable to retain RPA2 foci ..." -the result (Fig. 6C and D) seems to show just the opposite, i.e. RPA foci persist upon SLFN11, so please fix the sentence.
Referee #2:
In this manuscript, the authors show that SLFN11 protein physically interacts with the RPA complex and is recruited to the sites of DNA damage in a RPA-dependent manner. They also show that RPA foci, ssDNA generation and checkpoint activation persist longer in slfn11-deficient cells. By contrast, SLFN11 overexpression accelerates checkpoint shut off.
The data in the manuscript are interesting and generally of good quality.
The major problem with this manuscript is the conclusion: "Slfn11 promotes removal of RPA from ssDNA and facilitates ssDNA degradation". What the manuscript shows is that RPA foci, ssDNA generation and checkpoint activation persist longer in slfn11-deficient cells. The fact that Slfn11 overexpression has the opposite effects does not demonstrate that it is directly involved in RPA removal. Another possibility to explain the above phenotypes is that RPA and ssDNA persistence are due to defects of slfn11-deficient cells to repair DNA lesions. The authors should tone down the conclusion and consider alternative explanations. Also the conclusion on pag 13 that "Slfn11 is a recombination inhibitor" based on the finding that SCE is elevated in slfn11-deficient cells is an overinterpretation. Again, it could be due to defects in DNA repair pathways that channel DNA lesions into SCE.
Minor point: The upper part of Figure 2E is not aligned with the gel blots.
Referee #3:
The manuscript of Mu and coworkers provides insights into the potential molecular mechanism by which SLFN11 sensitizes cancer cells to DNA damage agents. The authors propose that SLFN11 removes RPA complexes induced by DNA damage by interacting with RPA1, resulting in the impairment of checkpoint maintenance (but not its initiation) and inefficient homologous recombination. This effect of SLFN11 on RPA is dependent on RPA1 and the c-terminal segment of SLFN11 but does not appear to be related to the putative helicase activity of SLFN11. The authors used several cellular systems, such as SF268/SLFN11 knockout cells and HeLa/SLFN11 expressing cells, to study this phenomenon, and the results are convincing. However, several of the conclusions need to be clarified and demonstrated by additional experiments. 1. The SLFN11-dependent differences in cell cycle checkpoint responses ( Fig. 2D ) showed differential cell cycle progression (arrest) in response to CPT in SLFN11 proficient vs. deficient cells. Therefore, cell cycle analyses should be provided to determine whether the differences in checkpoint response and HR could be due to the fact that SLFN11-proficient cells arrest their cell cycle progression while SLFN11-deficient cells continue cell cycle progression. If SLFN11-proficient cells have more S phase population or faster cell cycle progression than SLFN11-negative cells, the higher RPA foci and HR in SLFN11-negative cells could be caused by cell cycle differences. Such results should be included. 2. Whether the effects of SLFN11 are direct (via RPA) or indirect (via cell cycle [see above] or due to the RNA effect of SLFN11 proposed by Li, M. et al. Nature 2012) should be addressed in the Discussion. 3. Because of the proposed critical interaction between SLFN11 and RPA, RPA hyperphosphorylation by replicative DNA damage induced by CPT should be examined and discussed (Shao, R.G. et al., EMBO J. 1999) . What is the status of RPA phosphorylation in SLFN11 knockout or overexpressing cells under CPT treatment? 4. In figure 3B , "% cell with foci" in shCon and shRPA are shown, but what about the intensity of the foci? Because the reduction of RPA protein is almost 100% in Figure 3C , it would be important to determine whether the intensity of RPA foci counted as positive cells would be weaker in shRPA cells than shCon cells, and whether it is also the case for the SLFN11 foci.
5. Figure 4D does not match the legend (CPT 1 uM for 1h treatment, and 14 days incubation before colony counting)? 6. Figure 4D : experiments should be extended to a wider dose range for CPT. 7. The authors should provide survival data for SF268/SLFN11 knockout cells and SF268/SLFN11 knockout cells with re-introduction of SLFN11 under CPT or IR treatment compared with SF268 parental cells. So far, there is no report showing that SLFN11 determines IR and UV sensitivity. Assuming that RPA removal by SLFN11 is the causal factor that determines hypersensitivity to CPT in SFLN11-positive cells, SLFN11-positive cells should be also sensitive to IR and UV that induce RPA foci as shown in Figure 1B -D. 8. In Figure 6 E, there is a few folds increase in the amount of RPA1 and 2 bound to chromatin; however, in the Immunofluorescence data in Figure 6A -B, the foci number and size does not increase accordingly. Does it mean that the increase of RPA1 or 2 chromatin bound fractions correspond to a pan increase rather than focal one? 9. In Figure 7 , the cell viability of SF268/SLFN11 knockout cells recomplemented with WT SLFN11 and SLFN11 ∆5 and the SLFN11 helicase mutant cells should be shown to compare with SF268/SLFN11 knockout cells. 10. RPA polymerization normally occurs during DNA replication. Does SLFN11 impact normal replication? This point should be addressed and discussed?
1st Revision -authors' response 22 September 2015
We would like to thank all the reviewers for their careful and constructive comments on our manuscript. In the last two months, we have conducted a number of experiments as suggested by the reviewers. We hope that these new experimental findings address reviewers' concerns and provide additional support to our main conclusions. According to the reviewer's suggestion, we have also revised the Discussion section. Below is our point-by-point response to the reviewers' critiques:
SLFN11 was shown by Pommier and others to impart cellular sensitivity to topoisomerase poisons and other DNA damaging agents when present in elevated amounts (Zoppoli, PNAS, 2012; Barretina, Nature 2012 As suggested by this reviewer, we have now performed immunostaining experiments to examine whether the C-terminal region of SLFN11 is essential for its foci formation. As shown in the revised Figure 3E , the SLFN11 D5 mutant failed to form DNA damage-induced foci. Figure 4A and 4B, while wild-type SLFN11 was able to hydrolyze ATP, the K605M/D668A mutant failed to do so. These results are consistent with our original hypothesis that the putative RNA helicase activity of SLFN11 is not essential for its role in the regulation of DNA damage response.
The authors have the tool to estimate by immunoblotting the total number of molecules of SLFN11
in various cell lines relative to RPA copy number; this will inform us whether SLNF11 acts catalytically or stoichiometrically on RPA-ssDNA.
As suggested by this reviewer, we have now examined the protein levels of RPA1 and RPA2 in several human cell lines. As shown in the revised Figure 1A , RPA was expressed at similar levels in all cell lines tested.
5. The authors should check the level of cellular RPA in these cell lines before and after DNA damage to be sure that the steady level of RPA is not affected by SLFN11.
As suggested by this reviewer, we have now examined the protein levels of RPA in HeLa, U2OS, and SF268 cells before and after DNA damage. As shown in the revised Figure 4B , 4C, and 4F, overexpressing (HeLa and U2OS) or silencing (SF268) SLFN11 has no effect on the stability of RPA either with or without CPT treatment.
Can the authors assure us that the co-IP and pulldown of SLFN11 with RPA or RPA1 was not caused by RNA/DNA? This is a real concern knowing that these proteins bind nucleic acid.
We agree with the reviewer and have now repeated the co-immunoprecipitation experiments using benzonase-treated cell extracts (500 U/ml) to exclude the possibility that the interaction occurs indirectly via DNA/RNA bridging. As shown in the revised Figure 2C and 2D, SLFN11 was clearly detected in the immunoprecipitations obtained with the anti-RPA2 antiserum, and vice versa.
For the pull-down assays, we purified the MBP-tagged RPA1, RPA2, RPA3, and MBP alone under same conditions; however, only MBP-RPA1 was able to pull down SLFN11, indicating that the interaction between RPA1 and SLFN11 is direct (Please see Figure 2E ). (Fig. 7D) Figure 1A , Figure 4B , 4C and 4F, the expression levels of RAD51 in all cell lines tested are similar. We further examined RAD51 protein levels and its foci formation in SLFN11-deficient SF268 cells re-complemented with either wild-type or SLFN11 mutants. As shown in the revised Figure 7B -7D, while SLFN11 has no effect on the stability of RAD51 either with or without CPT treatment, it compromises the cell's ability to retain RAD51 foci after CPT withdrawal. These results are in agreement with our observation that BrdU-labeled ssDNA persisted for longer periods of time in SLFN11-deficienct SF268 cells than in SLFN11 wild-type SF268 cells after CPT withdrawal. Based on these results, we proposed that SLFN11 was able to destabilize the RPA-ssDNA intermediates and thus compromise the cell's ability to retain both RPA and RAD51 foci after CPT withdrawal. This is different from the mediator proteins, such as BRCA2 and PALB2, which can facilitate the replacement of RPA bound to ssDNA with RAD51 and therefore assist in the formation of RAD51 foci. Thanks for the suggestion! The same issue was also raised by reviewer #2. We have now toned down our claims and discussed other possibilities in the revised manuscript.
I question the model regarding SLFN11 function
I have a major issue with the claim that SLFN11 "removes
The Pommier PNAS paper did a nice job documenting the effect of SLFN11 in sensitizing cells to topoisomerase poisons. The authors should discuss the PNAS study more thoroughly.
We agree with this reviewer and have now discussed the PNAS study more thoroughly in the revised manuscript.
Minor Issues:
Fig. 2E: the lanes in the two panels are misaligned. Please fix this problem.
Sorry, it is now corrected.
I can't figure out why the authors cite so many RPA references (page 4 onto page 5). Wouldn't a review or two suffice?
We apologize for the inaccuracy in our citation. We have now amended the manuscript accordingly. Thanks for the suggestion! The same issue was also raised by reviewer #1. We have now toned down our claims and discussed these possibilities in the revised manuscript.
Page
Also the conclusion on pag 13 that "Slfn11 is a recombination inhibitor" based on the finding that SCE is elevated in slfn11-deficient cells is an overinterpretation. Again, it could be due to defects in DNA repair pathways that channel DNA lesions into SCE.
We agree with this reviewer and have now toned down our claims in the revised manuscript.
Minor point:
The upper part of Figure 2E is not aligned with the gel blots.
Sorry, it is now corrected.
Referee #3: Thanks for the suggestion! We have now discussed these possibilities in the revised manuscript.
Because of the proposed critical interaction between SLFN11 and RPA, RPA hyperphosphorylation by replicative DNA damage induced by CPT should be examined and discussed (Shao, R.G. et al., EMBO J. 1999). What is the status of RPA phosphorylation in SLFN11 knockout or overexpressing cells under CPT treatment?
As suggested by this reviewer, we examined the phosphorylation status of RPA2 in SLFN11 knockout or overexpressing cells under CPT treatment. As shown in the revised Figure 4F , SLFN11 silencing did not result in any detectable change in initial RPA2 phosphorylation upon CPT treatment, but blocked the rapid decline of RPA2 phosphorylation after CPT withdrawal. Consistently, both HeLa and U2OS cells overexpressing exogenous SLFN11 displayed a specific defect in the maintenance of RPA2 phosphorylation, but not the initial RPA2 phosphorylation (Please see the revised Figure 4B and 4C). These data support our original hypothesis that SLFN11 inhibits maintenance but not initiation of DNA damage checkpoint. We have now cited and discussed this paper in the revised manuscript. figure 3B , "% cell with foci" in shCon and shRPA are shown, but what about the intensity of the foci? Because the reduction of RPA protein is almost 100% in Figure 3C , it would be important to determine whether the intensity of RPA foci counted as positive cells would be weaker in shRPA cells than shCon cells, and whether it is also the case for the SLFN11 foci.
In
We agree with the reviewer that it is important to quantify IF data at foci. Thus, we used the NIH image J program to re-analyze RPA2 and SLFN11 foci formation in the presence or absence of RPA1/Mre11/CtIP. Images were captured at identical exposure time, converted into 8-bit gray-scale pictures and the fluorescence intensity threshold was set based on a black and white intensity scale ranging between 50 to 255. When the data were analyzed using the Image J software, results were similar to those we obtained previously (Please see the revised Figure 3B and 3G ).
To further demonstrate that RPA is required for SLFN11 recruitment to sites of DNA damage, we performed laser microirradiation experiments. As shown in the revised Figure 3D , RPA1 depletion reduced both RPA2 and SLFN11 recruitment. Importantly, the defects in RPA2 and SLFN11 recruitment in RPA1-depeletd cells were restored by re-introduction of RPA1 (the RPA1 shRNA#1 targets the 3' UTR of RPA1 transcript).
In order to more accurately reflect the knockdown efficiency of RPA1 shRNAs, we have now provided both short time and long time exposure of anti-RPA1 immnuoblotting in the revised Figure 3C .
Figure 4D does not match the legend (CPT 1 uM for 1h treatment, and 14 days incubation before colony counting)?
We apologize for the mistake. At 24 hr after seeding, cells were treated with various doses of CPT (20 nM, 40 nM, and 100 nM). The medium was replaced 24 hr later, and cells were then incubated for 14 days before colony counting. We have now revised the Figure legend accordingly. Figure 4D : experiments should be extended to a wider dose range for CPT.
6.
As suggested by this reviewer, we have now performed the cell survival assays in cells treated with three different doses of CPT (20 nM, 40 nM, and 100 nM). Figure 1B -D.
Thanks for the suggestion! We have now performed these experiments as suggested. As shown in the revised Figure 7E and Supplementary Figure 4C and 4D, SLFN11-deficient SF268 cells exhibited decreased sensitivity to CPT, IR and UV as compared with SF268 parental cells. In addition, the reduced sensitivity to CPT, IR and UV in SLFN11-deficient SF268 cells can be restored by re-introduction of wild-type SLFN11.
8. In Figure 6 E, there is a few folds increase in the amount of RPA1 and 2 bound to chromatin; however, in the Immunofluorescence data in Figure 6A -B, the foci number and size does not increase accordingly. Does it mean that the increase of RPA1 or 2 chromatin bound fractions correspond to a pan increase rather than focal one?
Given that inter-observer subjectivity could greatly affect the quantification of focus formation, we decided to repeat Thanks for the suggestion! We have now performed these experiments as suggested. As shown in the revised Figure 7E and Supplementary Figure 4C and 4D, the reduced sensitivity to CPT, IR, and UV in SLFN11-deficient SF268 cells can be restored by re-introduction of wildtype SLFN11 and the K605M/D668A mutant, but not the D5 mutant. These results are consistent with our original hypothesis that the role of SLFN11 in regulating DNA damage response depends on a physical protein-protein interaction between SLFN11 and RPA1, but not its putative RNA helicase activity.
RPA polymerization normally occurs during DNA replication. Does SLFN11 impact normal replication? This point should be addressed and discussed?
As suggested by this reviewer, we have now performed the BrdU incorporation assays. As shown in the revised Supplementary Figure 2A , SLFN11 silencing did not markedly affect DNA replication in the absence of DNA damage. We have now included this data in the revised manuscript. Thank you for your patience while your revised study was assessed by two of the original referees. As you will see, while referee 1 is satisfied with the revised manuscript, referee 3 is not. However, upon cross-commenting, referee 1 does not agree with the concerns of referee 3, and given that referee 2 was already happy with the first version of this manuscript, we have decided that referee 3's concerns do not need to be addressed experimentally. However, please make sure that your response to these concerns are clearly addressed in the manuscript text. The referee comments are pasted below.
I also need to tell you that we do not have supplementary information anymore. Please label the supplementary figures "expanded view" figures EV1, 2, etc. and please upload a single file per expanded view figure. The figure legends for EV figures need to be added to the end of the main manuscript file. The full gel blots are source data and not an extra figure, and need to be uploaded as separate source data files, with one file per figure. You can find more information in our guide to authors online.
I also would like to suggest a few changes to the abstract as follows;
High expression levels of SLFN11 correlate with the sensitivity of human cancer cells to DNAdamaging agents. [OK?] However, little is known about the underlying mechanism. Here we show that SLFN11 interacts directly with RPA1 and is recruited to sites of DNA damage in an RPA1-dependent manner. Furthermore, we establish that SLFN11 inhibits checkpoint maintenance and homologous recombination repair by promoting the destabilization of the RPA-ssDNA complex, thereby sensitizing cancer cell lines expressing high endogenous levels of SLFN11 to DNAdamaging agents. Finally, we demonstrate that the RPA1-binding ability of SLFN11 is required for its function in the DNA damage response. Our findings not only provide novel insight into the molecular mechanisms underlying the drug sensitivity of cancer cell lines expressing SLFN11 at high levels, but also suggest that SLFN11 expression can serve as a biomarker to predict responses to DNA-damaging therapeutic agents.
Please let me know whether you agree with these changes.
EMBO reports papers are accompanied online by A) a short (1-2 sentences) summary of the findings and their significance, B) 2-3 bullet points highlighting key results and C) a synopsis image that is either exactly 211x157 pixels, or 550x200-400 pixels large. For the larger image the height is variable. You can either show a model or key data in the synopsis image. Please note that the smaller size is rather small and that text needs to be readable at the final size. Please send us this information along with the revised manuscript.
I look forward to seeing a final version of your manuscript as soon as possible. Please let me know if you have any questions.
REFEREE REPORTS
Referee #1:
The authors have done an excellent job addressing my points.
This study will constitute the basis for dissecting the regulatory role of SLFN11 in RPA turnover at DNA lesions. The DNA repair and cancer biology communities will find the study of interest. I am, accordingly, enthusiastic about its publication in the Journal.
Referee #3:
The revisions address some of the points raised in the previous round of reviews. Yet it number of critical issues remain: 1. The recruitment of SLFN11 to chromatin is based on one polyclonal antibody. Because this antibody is not commercially available and has not been used or reported before, it is critical to determine its specificity. The Western blot data in supplemental figures show an additional band at higher molecular weight. The whole Western blot needs to be shown across the broad range of molecular weight markers. It will be important to demonstrate similar results with additional antibodies, such as those published in previous SLFN11 papers. If those antibodies do not show the recruitment by immunofluorescence microscopy, the authors should discuss and explain why. 2. It would also be very important to show a full characterization of the SLFN11 recruitment to DNA damage sites: a. Time course experiments in CPT-treated cells before three hours and between three and six hours after treatment. b. Use of more than one cell type; c. Concomitant staining with RPA2, gammaH2AX and 53BP1 at these different time points. d. Include controls without drug treatment. The Zoppoli paper (supplemental) shows SLFN11 staining in the absence of drug treatment. This should be discussed. e. The control Flag-SLFN11 without treatment should be included in Fig. 3 . This is critical because the immunoprecipitation data in Fig. 3C show that SLFN11 binds RPA1 in the absence of CPT treatment.
3. The new cell cycle data show differences in cell cycle in the SLFN11 deficient cells, which is consistent with the Zoppoli paper supplemental data. This could explain the increased homologous recombinations as more cells are in late S phase. 4. The data are over-interpreted: The proposed conclusion is that RPA1 recruits Schlafen 11 to the DNA damage sites and antagonize the RPA binding appears probably too simplistic. Indeed why you would RPA be even detectable on chromatin in SLFN11 positive cells. Detailed time course of the two proteins (SLFN11, RPA) and even better with gammaH2AX may clarify this issue. The model shown in the last figure is inaccurate. SLFN11 is recruited by RPA1 directly at the first step. If SLFN11 dissociates RPA, why does RPA form foci at 3 hours? The title is potentially misleading. The study really suggests that SLFN11 is recruited to DNA damage sites by RPA1. The differential HR response could be (and believe is likely to be) indirect, and probably unrelated to the direct unloading of RPA1 by SLFN11.
Cross-comments from Referee #1:
All of the criticisms of reviewer 3 are entirely new and are, to me at least, unwarranted.
-Concerning the new Point #1 regarding the specificity of the antibody used to reveal endogenous SNF11, the authors have used Flag-tagged SNF11 and have examined mutants in the cytological experiments as well, so I do not believe that criticism is warranted.
-The experiments suggested in Point #2 will add more details but likely will not fundamentally change the conclusions, which are that (i) SNF11 interacts with RPA and is recruited to DSB sites via the latter, (ii) where it somehow destabilizes the RPA-ssDNA complex to compromise checkpoint maintenance and homologous recombination.
-As for Point #3 (this was the original Point #1 of the Reviewer), I believe that the authors have done a satisfactory job addressing it experimentally and also highlighting why the results cannot be explained solely by a cell cycle effect of over-expressing or ablating SNF11.
-Finally, about Point #4, I agree that the authors have not figured out exactly how SNF11 works (this same point was in my original review too). I do not object to including the model ( Figure 7F ) in the manuscript though, as it basically summarizes the data without making any specific suggestion regarding mechanism. In other words, it is useful as a graphical summary without any offensive element.
My bottom-line is that, the authors have done quite a bit of work to show that sensitization of cells to DNA damaging agents by SNF11 has to do with its ability to affect the stability of RPA on ssDNA associated with DNA lesions, and the results are in general supportive of that premise. I believe that the study is suited to EMBO R without any further revision.
